Mary Crowley Cancer Research Center

Dallas, Texas 75251

4 studies enrolling now · 54 studies all time

What they study most

Adrenocortical Carcinoma, Advanced Adult Hepatocellular Carcinoma, Advanced Breast Cancer, Advanced Cancer, Advanced Gastric Cancer, Advanced Malignancies, Advanced Nonsmall Cell Lung Cancer, Advanced Soft Tissue Sarcoma, Advanced Solid Tumor, Advanced Solid Tumors, Anal Squamous Cell Carcinoma, B-cell Lymphoma

Studies at this site

• A Study of ASP1002 in Adults for Treatment of Solid Tumors — Recruiting now
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors — Recruiting now
• Study of STP938 (Dencatistat) in Advanced Solid Tumours — Recruiting now
• A Study of LM-24C5 For Advanced Solid Tumors — Recruiting now
• A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 — Recruiting now
• Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) — Running, not enrolling
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer — Running, not enrolling
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface — Completed
• A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL — Completed
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies — Running, not enrolling
• Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma — Completed
• Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer — Completed
• Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) — Completed
• Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer — Running, not enrolling
• A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors — Completed
• BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients — Completed
• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab — Completed
• Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer — Completed
• A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma — Completed
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors — Completed
• Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. — Completed
• A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer — Completed
• A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors — Completed
• First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b — Stopped early
• Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors — Completed
• Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer — Completed
• A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body — Completed
• A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab — Completed
• Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors — Completed
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors — Running, not enrolling
• Safety Study of MGD009 in B7-H3-expressing Tumors — Stopped early
• A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer — Stopped early
• Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer — Status unconfirmed
• Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer — Stopped early
• Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 — Completed
• Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers — Completed
• A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer — Completed
• A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma — Completed
• A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors — Completed
• Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors — Stopped early
• A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer — Completed
• Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions — Completed
• First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies — Completed
• Phase 1 Study of ONT-10 in Patients With Solid Tumors — Completed
• Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer — Stopped early
• Oral Rigosertib for Squamous Cell Carcinoma — Completed
• Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer — Completed
• Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma — Completed
• Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors — Completed